CombinatoRx Drug Misses Primary Goal in Gum Disease Trial
Posted on: Friday, 9 June 2006, 06:00 CDT
A drug being developed by biopharmaceutical company CombinatoRx has failed to reach its primary endpoint of reducing inflammation in patients with a bacterial gum disease in a trial.
This trial was designed to determine how CRx-150, an immuno-modulating agent, would affect various systemic inflammatory markers in individuals with periodontitis in both the acute and chronic phase of immuno-inflammation.
The drug, CRx-150, did not reduce C-reactive protein (CRP) in the chronic inflammatory phase, the primary endpoint of the trial, as measured after 42 days.
There were small or no differences between CRx-150 and placebo for the other inflammatory markers measured including IL-1, IL-8, IL-12 and IFN-gamma.
"Further study of CRx-150 will be required to understand the magnitude of its effects, given the activity in the acute phase of this model, and we look forward to results of the CRx-150 phase II trial in patients with rheumatoid arthritis expected in the first half of 2007," commented Alexis Borisy, president and CEO of CombinatoRx.
Source: Datamonitor
Related Articles
- Reportlinker Adds Innovations and Trends in Clinical Trials: Microdosing (Phase 0 Trials), Adaptive Trials, Phase IV Trials and the Role of Information Technology
- ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
- CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
- Opexa Therapeutics Completes Patient Enrollment in Phase IIb Trial of Tovaxin(TM) for Treatment of Multiple Sclerosis
- Opexa Achieves Midpoint in Patient Admissions in Phase IIb Trial of Tovaxin(TM) for Multiple Sclerosis
- Opexa Begins Dosing Patients in Phase IIb Trial of Tovaxin(TM) for Multiple Sclerosis
- Millennium Begins Trial on Inflammatory Drug
- CORRECTING and REPLACING CombinatoRx Reports Phase 2 Data on CRx-150 in Human Inflammatory Disease Model
- CombinatoRx Reports Positive Results for CRx-170 in Phase 2 Proof-of-Concept Asthma Clinical Trial
- AVANIR Receives Special Protocol Assessment For Neurodex Neuropathic Pain Clinical Trial; Phase III Trial to Begin First Half of 2005
 |
 |
User Comments (0)
RSS Feeds